Plain-English translation of NCT07215182 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
Researchers are testing a new imaging scan called PET/CT to see if it can better monitor how advanced melanoma responds to immunotherapy. Currently, doctors use a standard imaging scan to track treatment progress. This trial compares the new scan to the standard one to see if it provides clearer, faster results that could help guide your care.
When patients with advanced melanoma receive immunotherapy, doctors need to know quickly whether the treatment is working. The new imaging scan being tested may be better at detecting how tumors respond to treatment and could help doctors make faster decisions about your care plan.
You likely qualify if…
You likely don't qualify if…
You would visit the hospital on two separate occasions: once before starting immunotherapy and again after three months of treatment. Each visit includes an imaging scan using the new tracer medication, plus two small blood samples. You would also be followed up 6 months after your final scan to track how you're doing. The imaging scans are in addition to your regular cancer care appointments.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Denmark
Phase
Testing effectiveness
Sponsor
Barbara Malene Fischer
Collaborators
Herlev Hospital
Enrollment target
~20 participants
Started
August 2025
Primary completion
August 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in October 2025.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.